JP2022517435A5 - - Google Patents
Info
- Publication number
- JP2022517435A5 JP2022517435A5 JP2021541712A JP2021541712A JP2022517435A5 JP 2022517435 A5 JP2022517435 A5 JP 2022517435A5 JP 2021541712 A JP2021541712 A JP 2021541712A JP 2021541712 A JP2021541712 A JP 2021541712A JP 2022517435 A5 JP2022517435 A5 JP 2022517435A5
- Authority
- JP
- Japan
- Prior art keywords
- enpp1
- viral vector
- enpp3
- signal peptide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025027352A JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794450P | 2019-01-18 | 2019-01-18 | |
| US62/794,450 | 2019-01-18 | ||
| US201962821692P | 2019-03-21 | 2019-03-21 | |
| US62/821,692 | 2019-03-21 | ||
| US201962877044P | 2019-07-22 | 2019-07-22 | |
| US62/877,044 | 2019-07-22 | ||
| PCT/US2020/014296 WO2020150716A1 (en) | 2019-01-18 | 2020-01-20 | Treatment of diseases involving deficiency of enpp1 or enpp3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025027352A Division JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517435A JP2022517435A (ja) | 2022-03-08 |
| JP2022517435A5 true JP2022517435A5 (https=) | 2023-01-31 |
| JP7724156B2 JP7724156B2 (ja) | 2025-08-15 |
Family
ID=71613451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541712A Active JP7724156B2 (ja) | 2019-01-18 | 2020-01-20 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
| JP2025027352A Pending JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025027352A Pending JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210187067A1 (https=) |
| EP (1) | EP3911153A4 (https=) |
| JP (2) | JP7724156B2 (https=) |
| KR (1) | KR20210142599A (https=) |
| CN (1) | CN113631033B (https=) |
| AU (1) | AU2020207967A1 (https=) |
| BR (1) | BR112021013941A2 (https=) |
| CA (1) | CA3126839A1 (https=) |
| IL (1) | IL284699A (https=) |
| MX (1) | MX2021008503A (https=) |
| WO (1) | WO2020150716A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3195071A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
| MX2023005836A (es) * | 2020-11-19 | 2023-08-17 | Inozyme Pharma Inc | Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6. |
| CA3231858A1 (en) * | 2021-09-24 | 2023-03-30 | Inozyme Pharma, Inc. | Lyophilized enpp1 polypeptide formulations and uses thereof |
| WO2023196820A2 (en) * | 2022-04-04 | 2023-10-12 | Inozyme Pharma, Inc. | Treatment of enpp1 deficiency and abcc6 deficiency |
| WO2025213135A1 (en) * | 2024-04-04 | 2025-10-09 | The Brigham And Women's Hospital, Inc. | Lipid nanoparticles for the treatment of vascular diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6894022B1 (en) * | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| JP4200100B2 (ja) * | 2001-11-07 | 2008-12-24 | アジェンシス，インコーポレイテッド | 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質 |
| EP1736553A1 (en) * | 2005-06-17 | 2006-12-27 | Centre National De La Recherche Scientifique | ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications |
| US8168586B1 (en) * | 2007-11-21 | 2012-05-01 | Celera Corporation | Cancer targets and uses thereof |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP3470089A1 (en) * | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| EP3194430A1 (en) * | 2014-09-16 | 2017-07-26 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| EP3967755B1 (en) * | 2014-12-19 | 2024-03-27 | Inozyme Pharma, Inc. | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum |
| EP4414028A3 (en) * | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| CA3032467A1 (en) * | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| CN120383683A (zh) * | 2018-08-31 | 2025-07-29 | 耶鲁大学 | Enpp1多肽及其使用方法 |
-
2020
- 2020-01-20 CA CA3126839A patent/CA3126839A1/en active Pending
- 2020-01-20 AU AU2020207967A patent/AU2020207967A1/en active Pending
- 2020-01-20 EP EP20741209.9A patent/EP3911153A4/en active Pending
- 2020-01-20 BR BR112021013941-9A patent/BR112021013941A2/pt unknown
- 2020-01-20 KR KR1020217025330A patent/KR20210142599A/ko not_active Ceased
- 2020-01-20 CN CN202080009084.9A patent/CN113631033B/zh active Active
- 2020-01-20 WO PCT/US2020/014296 patent/WO2020150716A1/en not_active Ceased
- 2020-01-20 MX MX2021008503A patent/MX2021008503A/es unknown
- 2020-01-20 JP JP2021541712A patent/JP7724156B2/ja active Active
-
2021
- 2021-02-17 US US17/178,127 patent/US20210187067A1/en not_active Abandoned
- 2021-07-08 IL IL284699A patent/IL284699A/en unknown
-
2022
- 2022-08-25 US US17/822,245 patent/US20230031809A1/en active Pending
-
2025
- 2025-02-21 JP JP2025027352A patent/JP2025084821A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517435A5 (https=) | ||
| KR102766238B1 (ko) | 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법 | |
| JP7208133B2 (ja) | 酸性αグルコシダーゼ変異体及びその使用 | |
| JP2024015194A (ja) | アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用 | |
| US20230048025A1 (en) | Adeno associated viral vectors | |
| CN113316639A (zh) | 用于治疗庞贝氏病的治疗性腺相关病毒 | |
| TW202023630A (zh) | 核酸分子及其用於非病毒基因療法的用途 | |
| JP2021500071A (ja) | ヒト翻訳後修飾ｖｅｇｆ−ｔｒａｐによる眼疾患および転移性大腸がんの処置 | |
| JP7654562B2 (ja) | 線維芽細胞増殖因子２３関連低リン血症性疾患の遺伝子療法 | |
| US20250084434A1 (en) | Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same | |
| KR20170036085A (ko) | 포유동물 rpe65의 높은 아소머로하이드롤라아제 활성 돌연변이 | |
| JP2020526203A (ja) | ヒトにおけるａａｖ遺伝子療法のための手段及び方法 | |
| WO2024255448A1 (zh) | 凝血因子fviii蛋白变体、表达载体和用途 | |
| CN109952114A (zh) | 用于治疗醛脱氢酶缺乏的基因疗法 | |
| EP4236999A1 (en) | Vectorized anti-tnf-alfa antibodies for ocular indications | |
| CN116829595A (zh) | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 | |
| JP2023548758A5 (https=) | ||
| WO2022094157A1 (en) | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof | |
| JP7576039B2 (ja) | 第ｉｘ因子バリアントおよび治療でのその使用 | |
| TW202417633A (zh) | 用於眼適應症之載體化抗TNF-α抑制劑 | |
| RU2021120107A (ru) | Лечение заболеваний, включающих дефицит enpp1 или enpp3 | |
| EP4237453A1 (en) | Vectorized tnf-alpha antagonists for ocular indications | |
| WO2021078834A1 (en) | Chimeric acid-alpha glucosidase polypeptides and uses thereof | |
| US11795207B2 (en) | Modified plasma clotting factor VIII and method of use thereof | |
| JP2022506174A (ja) | 改変第ｉｘ因子ポリペプチド |